Rates of adherence and persistence with allopurinol therapy among gout patients in Israel

Rheumatology (United Kingdom)

Volumn 52, Issue 6, 2013, Pages 1126-1131

  Zandman Goddard, Gisele ^a,b   Amital, Howard ^b,c   Shamrayevsky, Nadya ^b   Raz, Raanan ^b,d   Shalev, Varda ^b,d   Chodick, Gabriel ^b,d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

Adherence; Allopurinol; Gout; Persistence; Uric acid

Indexed keywords

ALLOPURINOL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GOUT; HEALTH CARE UTILIZATION; HEART INFARCTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SOCIAL STATUS;

ADHERENCE; ALLOPURINOL; GOUT; PERSISTENCE; URIC ACID;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLOPURINOL; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; ISRAEL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 84878144709     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes431     Document Type: Article

References (31)

1. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011;71:1413-39.
2. Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout-what are the treatment options? Expert Opin Pharmacother 2009; 10:1319-28.
3. Bhole V, de Vera M, Rahman MM et al. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010;62:1069-76.
4. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400-14.
5. Kim KY, Ralph SH, Hunsche E et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617.
6. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-5.
7. Weaver AL. Epidemiology of gout. Cleve Clin J Med 2008; 75(Suppl 5):S9-12.
8. Dalbeth N, So A. Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis 2010;69:1738-43.
9. Schlesinger N, Schumacher HR Jr, Beutler AM. Serum uric acid in acute gout. Ann Rheum Dis 1998;57:443-4.
10. Zhang W, Doherty M, Pascual E et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011;70:571-5.
11. McClory J, Said N. Gout in women. Med Health R I 2009; 92:363-4, 368.
12. Mikuls TR, MacLean CH, Olivieri J et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50: 937-43.
13. Riedel AA, Nelson M, Joseph-Ridge N et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81.
14. Grassi W, De AR. Clinical features of gout. Reumatismo 2012;63:238-45.
15. Neogi T, Hunter DJ, Chaisson CE et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
16. Harrold LR, Andrade SE, Briesacher BA et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
17. Chodick G, Amital H, Shalem Y et al. Persistence with statins and onset of rheumatoid arthritis: a populationbased cohort study. PLoS Med 2010;7:e1000336.
18. Janssens HJ, Fransen J, van de Lisdonk EH et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010;170:1120-6.
19. Zucker I, Chodick G, Grunhaus L et al. Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study. CNS Drugs 2012;26:537-47.
20. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006;28:1411-24.
21. Kopjar B, Sales AE, Pineros SL et al. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003;92:1106-8.
22. Chodick G, Heymann AD, Shalev V et al. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 2003;18:1143-6.
23. Chodick G, Shalev V, Gerber Y et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30: 2167-79.
24. Census of population and housing, Jerusalem. Israel Central Bureau of Statistics 1995.
25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;187-220.
26. Monev SD. How should hyperuricemia be treated in a patient with allopurinol hypersensitivity? Cleve Clin J Med 2001;68:597-8.
27. Treharne GJ, Lyons AC, Hale ED et al. 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? Rheumatology 2006; 45:1-5.
28. Sarawate CA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81:925-34.
29. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997;19:239-63.
30. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011;12:103.
31. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2012;June 7, Epub ahead of print.